Province opens eligibility to new drug to help those with cystic fibrosis
The Saskatchewan government has expanded public coverage for the cystic fibrosis medication Alyftrek to include patients aged six and older. This decision follows successful pricing negotiations and aims to improve quality of life for over 95 percent of eligible patients in the province.
Why it matters
Expanding access to specialized life-improving drugs significantly impacts public health outcomes and healthcare affordability for patients with chronic genetic conditions.
The province of Saskatchewan has announced that it is expanding the eligibility of those living with cystic fibrosis to a medication which improves lung function.
People in Saskatchewan will now be able to take Alyftrek, a medication available for those ages six years and older who meet the medical criteria. The drug will be used for patients who have one of the 266 different genetic mutations which cause CF.
Health Minister Jeremy Cockrill said. “Alyftrek has been shown to improve quality of life in patients with CF, so expanding coverage puts CF patients first by helping them to lead healthier lives.”
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in